Skip to content
  1. Home/
  2. Latest news/
  3. Innovation/
  4. What are autoantibodies?
What-Are-Autoantibodies-lede-1122.jpg

What are autoantibodies?

More than 200 million people worldwide are living with an autoantibody disease, which occurs when the body attacks its own cells, tissues and proteins.

Antibodies are proteins that guard against substances—such as bacteria, fungi, viruses and toxins—that enter your body like foreign invaders. Antibodies protect you by attaching to those invaders (also known as antigens) and triggering your body’s natural immune response to destroy them.

You can think of autoantibodies as misguided, or pathogenic, antibodies. Instead of reacting to the antigen, they respond to your body’s own proteins, leading—in some cases—to an abnormal immune response that attacks the cells, tissues and organs of your body and contributes to the development of autoantibody diseases.
“Autoantibody diseases comprise a large and varied group of more than 80 chronic conditions,” says Katie Abouzahr, Vice President, Autoantibody Portfolio Development Leader, Janssen Research and Development. They include hemolytic disease of the fetus and newborn, in which a mother’s immune system attacks her unborn child’s blood cells; warm autoimmune hemolytic anemia, which involves the premature destruction of healthy red blood cells; and myasthenia gravis, a disorder that’s characterized by fluctuating weakness in the skeletal muscles.

Autoantibodies can be markers of autoimmune diseases like rheumatoid arthritis or lupus. In fact, more than 2.5% of the population is affected by an autoantibody-driven autoimmune disease.

“Autoantibody diseases represent a significant area of unmet patient need,” says Abouzahr. “There are 240 million people worldwide, approximately 3% of the population, who suffer from autoantibody diseases, many without safe and effective treatment options.”

That’s why Johnson & Johnson is working on immunological advances to help address the need.

Watch this video to learn more about autoantibodies and their role in rare diseases:

hqdefault.jpg

Are You Affected by an Autoantibody Disease?

Learn more about two clinical research studies and eligibility requirements.

More from Johnson & Johnson

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

5 things we now know about colorectal cancer

Surprising new research suggests that people younger than 50 are getting diagnosed with the disease at record rates. For National Colorectal Cancer Awareness Month, find out how to protect yourself—no matter your age.